Cytological Examination of Malignant Pleural Effusion in Breast Cancer

NCT06657638 | Completed

• 1 other identifier: R.24.10.2828.R2
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

Malignant pleural effusion (MPE) is characterized by the presence of malignant cells. It can occur in 15% of patients with cancer and is a common manifestation in patients with metastatic disease. Breast cancer (BC) is the second most common cause of MPE and MPE occurring in 2- 11% of patients with BC. Breast cancer is a heterogeneous disease of malignant tumors with diversified morphology, clinical course, biologic behavior and prognosis, and accurate tumor classification is critical for a patient's care.

Conditions

Malignant Pleural Effusion

Keywords

malignant pleural effusion; breast cancer; Cytological examination

Outcome Measures

Primary Outcomes (1)

• Cytological examination of pleural effusion in breast cancer ( cell/unit)

  Diagnosis of pleural effusion by cytological examination

  6 months

Study Arms (1)

Cancer breast

malignant pleural effusion in breast cancer

Diagnostic Test: Thoracentesis

Interventions

Thoracentesis DIAGNOSTIC_TEST

Aspiration of pleural effusion

Cancer breast

Eligibility Criteria

• Age: 18 Years+
• Gender Eligibility Details: Cancer breast
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients are presented for thoracentesis with cytological examination of pleural effusion, if the appearance of visceral and parietal pleural was clearly and if malignant diagnosis of breast was confirmed on histological analysis of the biopsy material.

You may qualify if:

• Patients will be included if they are presented for thoracentesis with routine cytological examination of pleural effusion before biopsy or thoracoscopy, if the appearance of visceral and parietal pleural was clearly and if malignant diagnosis of breast was confirmed on histological analysis of the biopsy material.

You may not qualify if:

• Age \<18 years.
• Patients diagnosed with malignant pleural mesothelioma (MPM)
• Contraindication for pleurocentesis; patient refusing, coagulopathy and active skin infection

Sponsors & Collaborators

• Mansoura University Hospital: lead

Study Sites (1)

Mohamed AbdElmoniem

Al Mansurah, 35516, Egypt

Location

MeSH Terms

Conditions

Pleural Effusion, Malignant; Breast Neoplasms

Interventions

Thoracentesis

Condition Hierarchy (Ancestors)

Pleural Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Pleural Effusion; Pleural Diseases; Respiratory Tract Diseases; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Paracentesis; Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Therapeutics; Surgical Procedures, Operative; Investigative Techniques

Study Officials

• Mohamed AbdElmoniem

  Mansoura University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lecturer of chest medicine

Study Record Dates

• First Submitted: October 23, 2024
• First Posted: October 24, 2024
• Study Start: October 19, 2024
• Primary Completion: January 19, 2025
• Study Completion: April 19, 2025
• Last Updated: May 29, 2025

Record last verified: 2025-05

Locations

EG (1)